Pallas Capital Advisors LLC Has $527,000 Stock Holdings in United Therapeutics Corporation $UTHR

Pallas Capital Advisors LLC raised its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 60.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,833 shares of the biotechnology company’s stock after purchasing an additional 693 shares during the quarter. Pallas Capital Advisors LLC’s holdings in United Therapeutics were worth $527,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SVB Wealth LLC purchased a new stake in shares of United Therapeutics in the first quarter worth approximately $32,000. Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Sound Income Strategies LLC bought a new position in shares of United Therapeutics during the first quarter valued at approximately $49,000. State of Wyoming acquired a new stake in shares of United Therapeutics during the fourth quarter worth $62,000. Finally, Brooklyn Investment Group increased its stake in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 98 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total value of $4,237,310.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $14,168,409.01. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 172,116 shares of company stock valued at $63,256,557. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $417.57 on Friday. The stock has a fifty day moving average of $329.55 and a two-hundred day moving average of $310.67. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The company has a market capitalization of $18.84 billion, a PE ratio of 16.30, a price-to-earnings-growth ratio of 6.37 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the previous year, the business posted $5.85 earnings per share. The company’s quarterly revenue was up 11.7% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on UTHR shares. HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Bank of America raised their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Oppenheimer lifted their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Cantor Fitzgerald upped their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a report on Wednesday, September 10th. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, September 4th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $438.85.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.